15/12/20 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
14/12/20 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
16/11/20 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
President 59 -
Director TitleAgeSince
Director/Board Member 59 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
11/16/20 A Issuer sale

Director

131,728 0.3818%
11/16/20 A Issuer sale

Chief Financial Officer

41,038 0.1189%
11/16/20 A Issuer sale

Chairman

136,253 0.3949%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+0.81%+5.38%+39.50%+132.88% 1,271B
+1.45%+3.28%+46.10%+93.23% 683B
+0.48%+1.16%+26.86%+112.56% 520B
-0.48%+3.51%+39.36%+69.21% 389B
-0.19%-0.58%+56.97%+42.36% 362B
+0.13%+0.71%+26.74%+58.38% 304B
+0.74%+0.37%+3.62%+36.44% 286B
-0.46%+0.77%+38.08%+73.97% 253B
+0.34%+0.66%+34.18%+124.20% 208B
Average +0.38%+1.73%+34.60%+82.58% 475B
Weighted average by Cap. +0.58%+2.67%+36.83%+94.97%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock